AR067904A1 - Derivados de piperazina-amida - Google Patents

Derivados de piperazina-amida

Info

Publication number
AR067904A1
AR067904A1 ARP080103496A ARP080103496A AR067904A1 AR 067904 A1 AR067904 A1 AR 067904A1 AR P080103496 A ARP080103496 A AR P080103496A AR P080103496 A ARP080103496 A AR P080103496A AR 067904 A1 AR067904 A1 AR 067904A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
heteroaryl
aryl
heterocyclyl
fluor
Prior art date
Application number
ARP080103496A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40298643&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR067904(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR067904A1 publication Critical patent/AR067904A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

Estos compuestos se fijan sobre LXR alfa y LXR beta y pueden utilizarse como medicamentos para usar para enfermedades como diabetes mellitus, alzheimer, de la piel, cáncer, HIV, antilipídico. Procesos y composiciones farmacéuticas. Reivindicacion 1: Compuestos de la formula (1) en la que X es N o CH; Y es N o CH; R1 es alquilo inferior, (alcoxi inferior)-alquilo inferior, halogeno-alquilo inferior, alquenilo inferior, cicloalquilo, cicloalquil-alquilo inferior, arilo, aril-alquilo inferior, heterociclilo, heterociclil-alquilo inferior, heteroarilo o heteroaril-alquilo inferior, en los que un cicloalquilo, arilo, heterociclilo o heteroarilo puede estar opcionalmente sustituido por 1-5 sustituyentes elegidos con independencia entre el grupo formado por halogeno, alquilo inferior, alcoxi inferior, fluoralquilo inferior y fluor-alcoxi inferior; R2 es alquilo inferior, fluor-alquilo inferior, (alcoxi inferior)-alquilo inferior, cicloalquilo, cicloalquilalquilo inferior, arilo, aril-alquilo inferior, heterociclilo, heterociclil-alquilo inferior, heteroarilo o heteroaril-alquilo inferior, en los que un cicloalquilo, arilo, heterociclilo o heteroarilo puede estar opcionalmente sustituido por 1-5 sustituyentes elegidos con independencia entre el grupo formado por halogeno, alquilo inferior, alcoxi inferior, fluor-alquilo inferior, fluor-alcoxi inferior, alcoxi inferior-carbonilo y fenilo; R3 es arilo o heteroarilo, dicho arilo o heteroarilo puede estar opcionalmente sustituido por 1-5 sustituyentes elegidos con independencia entre el grupo formado por halogeno, CN, alquilo inferior, fluor-alquilo inferior, alcoxi inferior y fluor-alcoxi inferior; R4, R5, R6, R7, R8, R9, R10 y R11 con independencia entre sí son hidrogeno o alquilo inferior, o R4 y R5 están unidos entre sí, o R6 y R7 están unidos entre sí, o R8 y R9 están unidos entre sí, o R10 y R11 están unidos entre sí, para formar un anillo junto con el átomo de carbono al que están unidos, y -R4-R5-, -R6-R7-, -R8-R9- y/o -R10-R11- es -(CH2)2-6-; y sus sales farmacéuticamente aceptables.
ARP080103496A 2007-08-13 2008-08-11 Derivados de piperazina-amida AR067904A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07114219 2007-08-13

Publications (1)

Publication Number Publication Date
AR067904A1 true AR067904A1 (es) 2009-10-28

Family

ID=40298643

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103496A AR067904A1 (es) 2007-08-13 2008-08-11 Derivados de piperazina-amida

Country Status (17)

Country Link
US (1) US8288541B2 (es)
EP (1) EP2188266B1 (es)
JP (1) JP5220858B2 (es)
KR (1) KR101171507B1 (es)
CN (2) CN103772299A (es)
AR (1) AR067904A1 (es)
AU (1) AU2008288537B2 (es)
BR (1) BRPI0815479A2 (es)
CA (1) CA2695088C (es)
CL (1) CL2008002356A1 (es)
ES (1) ES2393822T3 (es)
MX (1) MX2010001742A (es)
PE (1) PE20090592A1 (es)
RU (1) RU2454412C2 (es)
TW (1) TWI364420B (es)
WO (1) WO2009021868A2 (es)
ZA (1) ZA201001061B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012033353A2 (ko) 2010-09-07 2012-03-15 서울대학교 산학협력단 세스터터핀 화합물 및 이들 물질의 용도
CN103172635B (zh) * 2011-12-21 2016-04-27 上海医药工业研究院 哌嗪或哌啶类化合物、其盐、中间体、制备方法及应用
SG11201405378VA (en) 2012-03-02 2014-09-26 Anayaderm Inc Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
EP2882496B1 (en) 2012-08-13 2019-10-09 The Rockefeller University Treatment and diagnosis of melanoma
EP3041834A4 (en) 2013-09-04 2017-01-18 Ralexar Therapeutics, Inc. Liver x receptor (lxr) modulators
EP3626712A3 (en) 2013-09-04 2020-04-15 Ellora Therapeutics, Inc. Liver x receptor (lxr) modulators
EP3091970B1 (en) 2014-01-10 2020-10-28 Rgenix, Inc. Lxr agonists and uses thereof
AU2017207291B2 (en) 2016-01-11 2023-06-15 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
BR112019005297A2 (pt) * 2016-09-21 2019-06-04 Vectus Biosystems Ltd composto, composição farmacêutica, e, métodos para tratamento de hipertensão ou pré-hipertensão e de fibrose.
CA3078981A1 (en) 2017-11-21 2019-05-31 Rgenix, Inc. Polymorphs and uses thereof
MX2022007164A (es) 2019-12-13 2022-09-12 Inspirna Inc Sales metálicas y usos de estas.
KR20220152159A (ko) * 2021-05-07 2022-11-15 엠비디 주식회사 신규한 헤테로사이클 화합물 및 이의 용도

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US530238A (en) * 1894-12-04 Guard for lathes
DK350383A (da) 1982-08-27 1984-02-28 Hoffmann La Roche Phosphorforbindelser
EP0398132B1 (de) 1989-05-18 1995-09-20 F. Hoffmann-La Roche Ag Phosphorverbindungen
WO1992016535A1 (de) 1991-03-15 1992-10-01 F.Hoffmann-La Roche Ag Diphosphonsaure derivate als zwischenprodukte in der herstellung von diphosphinliganden
US5256321A (en) 1992-07-10 1993-10-26 The Lubrizol Corporation Grease compositions
CN1164232A (zh) * 1994-09-26 1997-11-05 曾尼卡有限公司 作为抗血栓形成剂或抗凝血剂的氨基杂环衍生物
IL115420A0 (en) * 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
KR20000029984A (ko) * 1996-08-14 2000-05-25 사라 엔 람베쓰 치환된피리미딘유도체및이의약학적용도
MXPA04011691A (es) 2002-05-24 2005-09-12 Pharmacia Corp Moduladores del receptor x anilino hepaticos.
PL375527A1 (en) * 2002-06-29 2005-11-28 Zentaris Gmbh Arylcarbonylpiperazines and heteroarylcarbonylpiperazines and the use thereof for treating benign and malignant tumour diseases
WO2004076418A1 (en) * 2003-02-28 2004-09-10 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
FR2869904B1 (fr) * 2004-05-07 2006-07-28 Fournier S A Sa Lab Modulateurs des recepteurs lxr
AU2005267331A1 (en) * 2004-06-24 2006-02-02 Incyte Corporation Amido compounds and their use as pharmaceuticals
DE102005000666B3 (de) * 2005-01-04 2006-10-05 Sanofi-Aventis Deutschland Gmbh Sulfonylpyrrolidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2142533B1 (en) * 2007-03-30 2011-11-16 F. Hoffmann-La Roche AG Imidazolidinone derivatives

Also Published As

Publication number Publication date
RU2010108943A (ru) 2011-09-20
TW200916463A (en) 2009-04-16
CN101778831B (zh) 2014-08-20
US20090048264A1 (en) 2009-02-19
CA2695088C (en) 2013-03-12
PE20090592A1 (es) 2009-05-03
ZA201001061B (en) 2010-11-24
ES2393822T3 (es) 2012-12-28
BRPI0815479A2 (pt) 2015-02-10
AU2008288537B2 (en) 2011-03-24
RU2454412C2 (ru) 2012-06-27
MX2010001742A (es) 2010-03-10
EP2188266A2 (en) 2010-05-26
CN103772299A (zh) 2014-05-07
US8288541B2 (en) 2012-10-16
AU2008288537A1 (en) 2009-02-19
CL2008002356A1 (es) 2009-05-29
WO2009021868A3 (en) 2009-04-09
EP2188266B1 (en) 2012-10-17
CN101778831A (zh) 2010-07-14
TWI364420B (en) 2012-05-21
JP5220858B2 (ja) 2013-06-26
WO2009021868A2 (en) 2009-02-19
CA2695088A1 (en) 2009-02-19
KR20100043096A (ko) 2010-04-27
JP2010535834A (ja) 2010-11-25
KR101171507B1 (ko) 2012-08-07

Similar Documents

Publication Publication Date Title
AR067904A1 (es) Derivados de piperazina-amida
AR065863A1 (es) Derivados de imidazolidinona
AR079327A1 (es) Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
AR077935A1 (es) Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina
AR012825A1 (es) Piridinas substituidas como inhibidores selectivos de ciclooxigenasa 2, una composicion farmaceutica que las contiene y su uso para la fabricacion de medicamentos
PE20190705A1 (es) COMPUESTOS DE BENZO[b] TIOFENO COMO AGONISTAS DE STING
CO6210729A2 (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona procedimientos para su preparacion y su uso como agente farmaceutico
PE20091099A1 (es) Derivados de aminobenzamida como agentes utiles para controlar parasitos animales
DOP2006000063A (es) Derivados de ciclopropanocarboxamida
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
DOP2014000055A (es) Derivados de pirrolopirimidina y purina
AR058362A1 (es) Derivados de isoquinolina - aminopirazol su obtencion y su utilizacion como agentes farmaceuticos
AR057906A1 (es) Derivados de pirimidona biciclicos sustituidos y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad anormal de gsk3beta.
ECSP055636A (es) Acidos tienil-hidroxamicos sustituidos, y su uso para tratar enfermedades asociadas con la actividad enzimatica de la histona desacetilasa
AR072224A1 (es) Derivados de pirimidona sustituidos
AR087668A1 (es) Derivados de oxazina y su uso en el tratamiento de enfermedades
UY28564A1 (es) Compuestos quimicos
UY28578A1 (es) Derivados de amida
AR077977A1 (es) Compuestos y composiciones como inhibidores de cinasa de proteina
CL2004000917A1 (es) Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa
BR112014014909A2 (pt) agonistas de tgr5 não sistêmicos
AR054024A1 (es) Derivados de piridina -3- carboxamida como agonistas inversos de cb1
DOP2015000169A (es) Compuestos tetracíclicos sustituidos con heterociclo y usos de los mismos para el tratamiento de enfermedades víricas
AR066095A1 (es) Compuesto de oxadiazol su uso para preparar un medicamento composicion farmaceutica que lo comprende y procedimiento para prepararla

Legal Events

Date Code Title Description
FA Abandonment or withdrawal